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Alzheimer disease (AD) is the most common neurodegenerative disorder worldwide and is at present, incurable. The 
accumulation of toxic amyloid-beta (Aβ) peptide aggregates in AD brain is thought to trigger the extensive synaptic loss and 
neurodegeneration linked to cognitive decline, an idea that underlies the ‘amyloid hypothesis’ of AD etiology in both the familal 
(FAD) and sporadic forms of the disease. Genetic mutations causing FAD also result in the dysregulation of neuronal calcium 
(Ca2+) handling and may contribute to AD pathogenesis, an idea termed the ‘calcium hypothesis’ of AD. Mutations in presenilin 
proteins account for majority of FAD cases. Presenilins function as catalytic subunit of γ-secretase involved in generation of Aβ 
peptide Recently, we discovered that presenilns function as low-conductance, passive ER Ca2+ leak channels, independent of 
γ-secretase activity. We further discovered that many FAD mutations in presenilins result in loss of ER Ca2+ leak function activity 
and Ca2+ overload in the ER. These results provided potential explanation for abnormal Ca2+ signaling observed in FAD cells with 
mutations in presenilns. Our latest work on studies of ER Ca2+ leak channel function of presenilins and implications of these 
findings for understanding AD pathogenesis are discussed in this article.  
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1  Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common type of 
age-related dementia. It is a worldwide epidemic which 
currently affects approximately 27 million people and be-
cause there is no known cure or therapy that significantly 
slows disease progression, this number is projected to 
quadruple by 2050 [1]. Clinical characteristics of AD in-
clude a decline in memory, particularly in short-term and 
working memory, apathy, depression, impaired judgement, 
disorientation, confusion, changes in behaviour and diffi-
culty speaking, swallowing and walking. The key patholog-
ical hallmarks of AD are extensive neurodegeneration of the 
median temporal lobe (the hippocampus in particular), pari-
etal lobe, select regions of the frontal cortex and cingulate 
gyrus [2,3]; the presence of extracellular senile plaques 
composed of dense-core deposits of amyloid β peptide (Aβ), 
dystrophic neuritis and activate microglia [4,5]; and intra-
cellular neurofibrillary tangles (NFTs) comprised of hyper- 
phosphorylated microtubule-associated protein tau (MAPT) 
[6]. The majority of AD cases are sporadic (SAD) and 
characterized by the late age of disease onset (>60 years of 
age). A small percentage (1%–2%) of all AD cases are 
characterized by an earlier onset (<60 years) and genetic 
inheritance, known as familial AD (FAD). Mutations in the 
genes encoding presenilin-1 (PSEN1), presenilin-2 (PSEN2) 
and amyloid precursor protein (APP) account for more than 
50% of autosomal-dominant FAD cases [4,5,7,8]. Mutations 
in the MAPT gene do not lead to AD but instead result in a 
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variant of frontotemporal dementia (FTDP17) [6,9,10].  
2  Presenilins and familial Alzheimer’s disease 
The majority of FAD is caused by missense mutations in the 
PSEN1 and PSEN2 genes, which display 80% sequence 
homology. Since the discovery of their potential involve-
ment in AD pathogenesis over 16 years ago [11], 182 muta-
tions in PSEN1 and 14 in PSEN2 have been identified to be 
causative in FAD (www.molgen.ua.ac.be/ADMutations) 
[12,13]. Presenilins (PSs) belong to the family of aspartic 
proteases and they are involved in Regulated Intramem-
brane Proteolysis (RIP), a mechanism that is used to cleave 
peptide bonds within the lipid bilayer [14,15] (reviewed in 
[16]). Presenilins are 50 kD holoproteins that contain 9 
transmembrane (TM) domains [17,18] and they reside pri-
marily in the endoplasmic reticulum (ER) membrane [19] 
with the amino-terminal oriented towards the cytosol and 
the carboxy-terminal toward the ER lumen (Figure 1). The 
PSs aggregate with nicastrin, anterior pharynx defective 1 
(Aph-1) and presenilins enhancer 2 (Pen-2) subunits to 
produce the multimeric γ-secretase complex, which is 
transported to the cell surface and endosomal structures to 
cleave type I transmembrane proteins such as Notch and the 
amyloid precursor protein (APP). Following assembly, PS1 
and PS2 holoproteins undergo endoproteolysis in the cyto-
solic loop between TM6 and TM7, resulting in the genera-
tion of a 35 kD amino-terminal fragment (PS-NTF) and an 
18–20 kD carboxy-terminal fragment (PS-CTF), which re-
main associated with each other in the “mature” γ-secretase 
complex [20–27]. The cleavage of APP sequentially by 
β-secretase then γ-secretase results in the generation and 
release of Aβ, the principal constituent of the amyloid β in 
the brains of AD patients [27,28]. Consistent with the role 
of PSs as the catalytic subunits of γ-secretase [8,27,28], 
PS-FAD mutations result in a shift in the proteolysis of APP 
such that there is an increase in the production the hydro-
phobic, aggregation-prone 1-42 Aβ fragment, increasing 
Aβ42/40 ratio and contributing to Aβ plaque formation 
[27–29]. In addition, loss of PSs or mutation of the catalytic 
aspartates D257 or D385 in TM6 and TM7, respectively, 
affect APP processing (Figure 1) [27]. 
3  Presenilins and intracellular calcium signaling 
The identification of the biological functions of PS has been 
a global effort since the discovery that they were involved 
in AD pathogenesis. It appears that PSs have a wide range 
of functions beyond RIP and γ-secretase function, including 
β-catenin regulation, protein trafficking, apoptosis in both 
mammals and plants (reviewed in [16]). Interestingly, many 
PS-FAD mutations result in deranged neuronal calcium 
(Ca2+) signaling (reviewed in [30–33]), which suggests a 
role for PS in the regulation of intracellular Ca2+ signaling. 
The connection between PS-FAD mutations and abnormal 
Ca2+ signaling has been known approximately 2 decades 
[34], however, the molecular mechanism(s) behind this ob-
servation are still controversial [30–33]. 
A consistent observation is that PS-FAD mutations pre-
dominantly result in the exaggerated release of Ca2+ from 
overloaded ER stores. Skin fibroblasts from human patients 
that harbour a mutation in PS1-A246E showed exaggerated 
Ca2+ release from IP3-gated stores compared to controls af-
ter treatment with bombesin and bradykinin [34]. Altera-
tions in Ca2+ signalling were detected before the develop-
ment of overt clinical symptoms and such changes were not 
present in cells from subjects that failed to develop AD [35]. 
These initial results were recapitulated experimentally in 
various model systems expressing FAD-related mutations in 
PS and the data suggested that in addition to contributing to 
altered γ-secretase function, PS mutations had a significant 
impact on Ca2+ signalling in AD models. These early ob-
servations supported the “Ca2+ hypothesis of AD” which 
states that deranged Ca2+ signaling plays an important role 
in AD pathogenesis [30–33,36,37].  
More recently, primary cortical neurons from mice ex-
pressing mutant PS1 displayed similar altered IP3R Ca
2+ 
signalling [38] which were attributed to increased ryanodine 
receptor (RyanR) expression and recruitment [39,40]. In 
addition, RyanR protein levels and channel function are 
increased in mouse models of containing PS mutations 
PS1-M146V and PS2-N141I [41–43]. Clinical mutations of 
PS2 also enhanced Ca2+ release from IP3R-gated ER stores 
[44]. PS1 mutations and genetic knockout attenuate capaci-
tative Ca2+ entry (CCE), a refilling mechanism for depleted 
ER Ca2+ stores [45–51]. The PS1-M146V mutation aug-
mented Ca2+ release from IP3- and caffeine- gated stores in 
hippocampal and cortical neurons in 3×Tg-AD mice 
[39,40,52]. The gating of IP3R can be modulated by 
PS1-M146L and several other PS1-FAD mutants [53,54]. 
Xenopus laevis oocytes expressing PS1-M146V have in-
creased sarco-/endoplasmic reticulum Ca2+ ATPase 
(SERCA) activity compared to those with wild-type PS1 
[55], a mechanism that could contribute to the overfilling of 
ER Ca2+ store. Defects in store-operated Ca2+ entry have 
been reported in studies with PS1-FAD and PS knockout 
cells. Taken together, PSs have profound effects on the ac-
tivity and/or expression of many proteins involved in intra-
cellular Ca2+ signalling. 
4  Presenilins are ER Ca2+ leak channels 
Recently, we discovered that PSs function as low-conduct- 
ance, passive ER Ca2+ leak channels, independent of 
γ-secretase activity [56]. We found that many FAD muta-
tions in PS1 disrupt this Ca2+ leak function [56–58], result-
ing in overloaded ER Ca2+ stores and exaggerated ER Ca2+ 
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release in double PS knock-out fibroblasts [56–58], cultured 
hippocampal neurons from PS double-knockout mice and 
PS1-M146V mutant neurons [51] and lymphoblasts from 
FAD patients [58]. These observations suggest that PS1 
plays a pivotal role in deranged Ca2+ in AD and they also 
provide further support for the contribution of PS1 to Ca2+ 
homeostasis in neurons. 
Our novel proposal that PSs function as Ca2+ or ion con-
ductance channels has been challenged [53,54]. In particular, 
it has been argued that PSs lack an ion conductance pore 
and therefore would not be able to function as ion channels 
[53,54]. The crystal structure of PS has not been elucidated 
and the presence of an ion conductance pore cannot be con-
firmed or refuted based on structural analysis studies. 
However, recent biochemical studies of PS1 by two inde-
pendent groups [59–62] have revealed the presence of a 
water-filled cavity within the hydrophobic membrane, 
which would allow for the hydrolysis required for proteo-
lytic cleavage by γ-secretase. These groups utilized cyste-
ine-scanning mutagenesis (SCAM), a technique that was 
developed to identify residues which line a pore of a chan-
nel [63,64]. In studies of PS1 it was determined that TM7 
domain containing the catalytic aspartate residue D385 is 
facing a water-filled cavity in the lipid bilayer. In contrast, 
TM6 domain containing D257 catalytic residue was not 
water accessible. It was reasoned that significant transloca-
tion of TM6 is required to support proteolytic cleavage of 
the γ-secretase substrates within the membrane [59–62] 
(Figure 1B). Again using SCAM, the investigators were 
also able to demonstrate the involvement of TM domain 9 
in forming the hydrophilic pore [60,61]. Being wa-
ter-accessible and highly flexible, TM domain 9 is poten-
tially involved in the translocation of substrates from the 
initial binding site to the catalytic site of PS1 [60]. Recent 
NMR studies of PS1-CTF in micelles revealed unusual fea-
tures of TM domains 7 and 9, where TM domain 7 was 
discovered to be a putative half-membrane-spanning helix 
and TM domain 9 was a kinked helix [65]. In addition, they 
discovered a higher rate of hydrogen-deuterium exchange in 
these regions, implying either higher exposure to the aque-
ous environment and/or increased dynamics [65]. These 
data further confirm the flexibility of TM domain 9 and the 
involvement of TM domain 7 and 9 in forming a water- 
filled catalytic core. 
Could this hydrophilic pore (Figure 1B) also serve as an 
ion conductance channel? Recently, in order to answer this 
question and to map the ion conductance pore in PS1, we 
systematically evaluated ER Ca2+ leak activity supported by 
a series of cysteine point mutants in TM6, TM7 and TM9 of 
mPS1 expressed in PS double knockout mouse embryonic 
fibroblasts [66]. Using Ca2+ imaging and stable cell rescue 
lines, our results indicated that TM7 and TM9, but not TM6, 
play an important role in forming the ion/Ca2+ conductance 
pore of PS1 [66]. These results are consistent with previous 
SCAM and NMR analysis of PS1 [59–62,65] and provide  
further support to our hypothesis that the hydrophilic cata-
lytic cavity of presenilins also constitutes the Ca2+ conduct-
ance pore. However, it is important to remember that Ca2+ 
channel function is supported by the holoprotein of PS1 in 
the ER [56] and γ-secretase function is supported by cleaved 
PS1 in the plasma membrane [67]. Therefore, these 2 func-
tions are mutually exclusive and never performed by the 
same PS1 molecule simultaneously (Figure 1B).  
What about the location and composition of the ion/Ca2+ 
conductance channel? Interestingly, it was discovered that 
PS1 forms homodimers in intact mammalian cells in fluo-
rescent lifetime imaging microscopy using differentially 
labeled PS1 constructs experiments [68]. It has been re-
ported that PS1 dimers affect γ-secretase activity and func-
tion [69–71]. However, the involvement of PS1 dimers and 
how the configuration relates to the ion conductance func-
tion of PS1 is not known. It was revealed that PS1 holopro-
teins with D257A mutation were also able to form dimers, 
suggesting that cleavage within the loop was not necessary 
for dimerization [68]. These data align with our finding that 
residues in TM domain 6, which contains D257, did     
not affect the Ca2+ channel function of PS1 and could sup-
port a possible homodimer configuration of PS1 for the ion 
channel [66]. Further experiments utilizing mutations of 
other TM domains that could be involved in the formation 
of the ion/Ca2+ conductance pore of PSs are required. For 
example, recent application of SCAM approach demon-
strated that TM1 of mPS1 is water exposed and facing the 
catalytic pore of γ-secretase [72]. However, for definitive 
information regarding the location and composition of the 
PS1 ion/Ca2+ conductance pore, the crystal structure of PS 
must be elucidated.  
5  ER Ca2+ leak and variant AD  
Clinical studies indicated that many patients with FAD mu-
tations in PS1 display significant phenotypic heterogeneity, 
including variable age of onset, penetrance, myoclonus and 
seizures, Parkinsonism, apraxia/ataxia, FTD and psychiatric 
symptoms [73–75]. There are also variations in PS1-FAD 
neuropathology. For instance, greater NFT formation, al-
tered amyloid β plaque composition, hippocampal sclerosis, 
the appearance of Pick bodies and neuropathological   
involvement of the basal ganglia and/or brainstem [73–75]. 
An intriguing subset of PS1-FAD patients manifest symp-
toms of spastic paraparesis (SP, known as variant AD), or 
progressive spasticity of the lower limbs [73–76]. The link-
age of SP to PS1-FAD mutations, R278T and M233T, was 
first reported in 1997 [77]. The PS1 deletion of exon 9 (∆E9) 
was associated with SP in a Finnish family [78]. However, 
not all patients carrying PS1-∆E9 within the same family 
will present with SP [79], which suggests the involvement 
of modifiers and environmental factors. Upon pathological 
examination of patients harbouring PS1-FAD mutations  
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Figure 1  ER Ca2+ leak and γ-secretase function of PS1. A, The domain structure of PS1. TM domains 1–9 are indicated. The yellow stars indicate the 
catalytic asparates D257 and D385. Based on biochemical [17,18] and structural [65] studies. B, ER Ca2+ channel (top) and γ-secretase (bottom) confor-
mations of hydrophilic pore in PS1. Adapted from [66]. Proposed arrangement of TM6, TM7, TM8 and TM9 is indicated. Amino acids are represented by a 
single letter code. Light blue residues are exposed to water in SCAM experiments and dispensible for ER Ca2+ leak activity. Dark blue residues are exposed 
to water and essential for ER Ca2+ leak activity. Stars indicate the D257 and D385. The model is based on SCAM analysis [59–62] and results of ER Ca2+  
leak assays [66]. 
associated with SP, their brains usually contain abundant 
large, non-cored amyloid-β plaques, named cotton wool 
plaques (CWP) composed primarily of Aβ42 peptide and 
lacking surrounding neuritic dystrophy and glial activation 
[8,73,80,81]. Patients also display corticospinal tract degen-
eration at the level of the medulla and the spinal cord [79]. 
It is believed that the accumulation of CWP plaques in the 
basal ganglia, brainstem and spinal cord is responsible for 
the Parkinsonism and spastic phenotypes clinically observed 
in these patients. The reasons for these unique clinical and 
pathological phenotypes observed in these PS1-FAD pedi-
grees are not understood [8,73–75,80,81]. 
Could this variant AD somehow be explained by the al-
tered ER Ca2+ signaling caused by PS1-FAD mutations? 
Over a series of experiments [56–58], we have tested a total 
of 23 FAD mutations in PS1, 1 FAD mutation in PS2 and 3 
FTD implicated PS1 mutations. We concluded that 14 FAD 
mutations abolished ER Ca2+ leak function of PS (Figure 
2A). These conclusions are based on the lack of channel 
activity in planar bilayers with recombinant PSs and by 
failure of these mutants to rescue Ca2+ signaling defects in 
PS DKO MEF cells. In contrast, another 10 FAD mutations 
in PS1 appeared to be functional and were able to rescue ER 
Ca2+ leak defects in PS DKO fibroblasts (Figure 2A). The 
PS1-∆E9 FAD mutant acted as a “gain of function” (GOF) 
mutant based on bilayer experiments [56]. Other functional 
PS1 mutants were able to rescue Ca2+ signaling defects in 
PS DKO MEF cells but were not tested in bilayers. These 
mutants may correspond to a GOF, normal function, or par-
tial loss of function mutations and were classified as “func-
tional”. All 3 PS1 mutants implicated in FTD (L113P, 
G183V, and Rins352) were functional in ER Ca2+ leak as-
say (Figure 2A). The Rins352 mutation is probably not 
pathogenic as the same patient also has a mutation in 
progranulin, which is most likely responsible for the disease 
[13]. The pathogenic status of the L113P and G183V muta-
tions remains to be elucidated. The “loss of function” (LOF) 
mutations are spread out through the sequence of PS1  
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Figure 2  Variant AD and ER Ca2+ leak function of PS1. A, Schematic 
representation of PS1-FAD mutations analyzed in ER Ca2+ leak function 
experiments. Adapted from [58]. The nine transmembrane domains (TM1– 
TM9) of presenilins, the γ-secretase catalytic aspartate residues (D257 and 
D385, yellow) and the site of the endoproteolytic cleavage of presenilins 
are shown. The effects of FAD mutations on ER Ca2+ leak activity of pre-
senilins are color coded – red color is used for LOF mutations, blue color is 
used for “functional” mutations. The positions of 3 PS1 FTD-implicated 
mutants are also shown (light blue color). B, Effects of PS1-FAD muta-
tions on ER Ca2+ levels and Aβ42/40 ratios. Adapted from [58]. For each 
PS1-FAD mutant the Aβ42/40 ratios and ER Ca2+ levels were normalized 
to the corresponding values for wild-type (WT) (open triangle). The 
PS1-FAD mutants with confirmed DCP pathology (M139V, M146L, 
A246E) are plotted as solid circles. The PS1-FAD mutants with confirmed 
CWP pathology (L166P, P436Q, P264L, ∆E8, E280G, ∆E9, T291P, 
C410Y) are plotted as open circles. The PS1-FAD mutants with unknown 
pathology (G384A, L85P) are plotted as open diamonds. The diagram is 
divided into 4 quadrants (I, II, III, IV) as shown and explained in the text. 
(within exons 5, 6, 7, 8, 11, and 12 of PSEN1 gene) and are 
mostly localized to the TM domains (Figure 2A). Most 
“functional” PS1 FAD mutations are concentrated in the 
initial portion of a large cytosolic loop between TM6 and 
TM7 (Figure 2A), the region encoded by exons 8 and 9 of 
the PSEN1 gene. 
Is there any correlation between ER Ca2+ leak phenotype 
of PS1-FAD mutants and clinical phenotypes of FAD pa-
tients with the same mutations? In our analysis we discov-
ered that PS1-∆E9 and most other PS1-FAD mutants that 
were “functional” for Ca2+ leak (L85P, P264L, R269G, ∆E8, 
E280G, T291P, N405S, and C410Y) segregated with the 
CWP pathology and/or SP clinical phenotype. Remarkably, 
all “functional” mutations are associated with CWP/SP 
phenotype and none of the “functional” mutations led to 
typical dense-core plaque (DCP) AD pathology. Based on 
these results we concluded that the disruption of both ER 
Ca2+ leak and γ-secretase function of PS1 causes pathologi-
cal changes in the brains of PS1-FAD patients. To represent 
these ideas quantitatively, we plotted the increase in 
Aβ42/40 ratio against the increase in ER Ca2+ levels for 
each of the PS1-FAD mutants (Figure 2B). The fold in-
crease values for Aβ42/40 ratios (Figure 2B) for each of the 
PS1 FAD mutants were extracted from http://www.molgen. 
ua.ac.be/ADMutations [12,13]. The change in ER Ca2+ lev-
els was plotted based on our studies of ER Ca2+ leak activity. 
We made an assumption that for LOF mutants the ER Ca2+ 
levels were increased 2 fold, for “functional” mutants the 
ER Ca2+ levels were unchanged, and for the GOF mutant 
PS1-∆E9 the ER Ca2+ levels were reduced by 10%. The 
Aβ42/40 ratios and ER Ca2+ levels were normalized to the 
corresponding values for the wild-type (WT, open triangle). 
The 3 PS1-FAD mutants with confirmed DCP pathology 
(M139V, M146L, A246E) [82–84] were plotted as solid 
circles, the 8 PS1-FAD mutants with confirmed CWP pa-
thology (L166P, P436Q, P264L, ∆E8, E280G, ∆E9, T291P, 
C410Y) [73,80,81] were plotted as open circles, and the 2 
PS1-FAD mutants with unknown pathology (G384A, L85P) 
were plotted as diamonds. For the remaining 9 PS1-FAD 
mutants (G217D, K239E, V261F, E273A, L420R, A426P, 
A431E, R269G, and N405S) Aβ42/40 values were not 
available and these mutants could not yet be plotted. The 
late onset, partially penetrant PS1-A79V mutation and 
PS2-N141I mutation were not plotted.  
The resulting diagram can be divided into 4 quadrants 
(Figure 2B): quadrant I (high ER Ca2+, small increase in 
Aβ42/40), quadrant II (high ER Ca2+, large increase in 
Aβ42/40), quadrant III (low ER Ca2+, small increase in 
Aβ42/40), quadrant IV (low ER Ca2+, large increase in 
Aβ42/40). Interestingly, all 3 mutations with confirmed 
DCP are located in quadrant I, and all mutations with con-
firmed CWP are located in quadrants II, III, or IV (Figure 
2B). Given these results, we propose that both ER Ca2+ 
dyshomeostasis and increases in Aβ42/40 ratios can play a 
role in development of AD pathology. If the pathology is 
driven by both ER Ca2+ overload and an increase in 
Aβ42/40 ratios, then the formation of DCP is favoured 
(quadrant I). However, if the pathology is primarily driven 
by an increase in the Aβ42/40 ratio, then the formation of 
Aβ42-enriched CWP plaques is strongly favored. We pro-
pose that this situation can occur when ER Ca2+ levels are 
not affected (quadrant III) or when ER Ca2+ levels are af- 
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fected but an increase in Aβ42/40 ratios is large (quadrant 
II). The extreme case of this situation is quadrant IV, which 
corresponds to both low ER Ca2+ levels and large increase 
in Aβ42/40 ratios (Figure 2B). Indeed, the only mutation 
located in quadrant IV (PS1-∆E9) results in the most robust 
and penetrant CWP/SP clinical phenotype [85,86]. The 
proposed classification has a predictive power. For example, 
we predict that mutations G384A (located in quadrant II) 
and L85P (located in quadrant III) should also be linked 
with CWP pathology. It will be of interest to test this pre-
diction experimentally. Although the pathological evalua-
tion of these mutants has not yet been reported, the SP clin-
ical phenotype has been previously described for PS1-L85P 
patients [87], consistent with our predictions.  
The proposed hypothesis provides a novel insight into 
the relative contributions of Ca2+ -driven and amyloid- 
driven pathological pathways in AD patients. Therefore, if 
pathology is primarily driven by an increase in Aβ42/40 
ratio, then formation of Aβ42-enriched CWP plaques is 
favored. It has been previously proposed that only muta-
tions that cause large increases in Aβ42/40 ratios, such as 
PS1-∆E9 and PS1-436Q, can lead to CWP plaques [76]. 
Our proposal can be considered as expansion of the same 
idea which now adds “Ca2+ dimension” to the “amyloid 
dimension”. In agreement with the earlier proposal [76], we 
argue that PS1-FAD mutations linked with large increases 
in Aβ42/40 ratio should yield CWP phenotype inde-
pendently from effects of the same mutation on ER Ca2+ 
leak (quadrants II and IV on Figure 2B). However, even 
PS1 mutations that have relatively small effects on Aβ42/40 
ratios would yield CWP phenotype if ER Ca2+ leak is not 
effected (quadrant III on Figure 2B). 
On the other hand, if pathology is driven by both Ca2+ 
dyshomeostasis and relatively modest increases in the 
Aβ42/40 ratio, then typical DCP or “diffuse” plaques are 
favored (quadrant I on Figure 2B). It is possible that the 
relative contribution of these pathways may vary in differ-
ent members of the same pedigree, resulting in a variable 
presentation of CWP/SP phenotype in most cases [73,80,81]. 
In agreement with this idea, the most robust CWP/SP phe-
notype was reported for PS1∆E9 mutant [78,85], which has 
the largest effect on γ-secretase activity and acts as a GOF 
mutant for ER Ca2+ leak channels (quadrant IV, Figure 2B). 
Our hypothesis indeed predicts that the mutant with these 
properties should shift the balance as far as possible towards 
pure amyloid-driven pathology and formation of CWP 
plaques. 
6  Neuronal Ca2+ signalling and sporadic AD 
What are the implications of these findings for sporadic AD? 
The age-related changes in neuronal Ca2+ signalling have 
been well established [88–90]. It has been shown that Ca2+ 
release from intracellular stores is increased in the aging 
neurons, similar to neurons that express PS1-FAD mutants 
with loss of ER Ca2+ leak leak function. Thus, it is possible 
that overloaded ER Ca2+ stores result in “accelerated aging” 
phenotype [91]. Other features of aging neurons include 
depolarized mitochondria, reduced cytosolic Ca2+ buffering 
capacity, and activation of calcineurin and calpains. All 
these changes indicate that aging neurons experience sig-
nificant dysregulation of intracellular Ca2+ handling. Con-
sistent with importance of Ca2+ signalling in sporadic AD, 
most sporadic AD patients present dense core plaque phe-
notype. However, some of sporadic AD patients also pre-
sent CWP pathology [84], suggesting that CWP are not spe-
cific for early onset FAD resulting from PS1 mutations. The 
evidence suggests that there is a significant and complex 
interplay between the “amyloid hypothesis” and the “Ca2+ 
dysregulation hypothesis” of AD pathogenesis, and it ap-
pears that PSs are master-regulators of these processes. It is 
possible that the relative contribution of “Ca2+-driven” and 
“amyloid-driven” pathogenic processes may vary between 
different brain regions, resulting in different abundance of 
CWP and DCP plaques in different areas of the brain for 
SAD and FAD patients. Future studies will be needed to test 
the proposed hypothesis and to relate our findings to under-
standing the pathogenesis of familial and sporadic AD. 
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